CAS 943319-70-8

Ponatinib

Description:

Ponatinib is a targeted therapy medication primarily used in the treatment of certain types of leukemia, particularly chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are resistant to other treatments. It is classified as a tyrosine kinase inhibitor, specifically designed to inhibit the BCR-ABL fusion protein, which is often responsible for the proliferation of cancer cells in these conditions. The chemical formula of ponatinib reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. It is characterized by its ability to cross the blood-brain barrier, making it effective for central nervous system involvement in leukemia. Ponatinib is administered orally and is known for its potential side effects, which can include cardiovascular issues, hypertension, and myelosuppression. Due to its potency and the risk of serious adverse effects, its use is typically reserved for patients who have not responded to other therapies. Monitoring and management of side effects are crucial during treatment with ponatinib.

Formula: C₂₉H₂₇F₃N₆O

InChI: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)

InChI key: InChIKey=PHXJVRSECIGDHY-UHFFFAOYSA-N

SMILES: C(#CC1=CC(C(NC2=CC(C(F)(F)F)=C(CN3CCN(C)CC3)C=C2)=O)=CC=C1C)C=4N5C(=NC4)C=CC=N5

Synonyms:

• 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide
• Ap 24534
• Ap24534
• Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-
• Iclusig
• Ponatinib
• AP24534(Ponatinib)
• 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
• Ponatinib hybrochloride
• AP24534 hybrochloride
• Ponatinib (AP24534)
• 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide Ponatinib(AP24534) AP 24534
• Ponatinib (with 4 ints.)

Ponatinib

CAS: 943319-70-8

Ponatinib

Formula: C₂₉H₂₇F₃N₆O

Purity: ≥98%

Color and Shape: Solid

Molecular weight: 532.56

Ref: 54-BUP14504

Ponatinib

CAS: 943319-70-8

Formula: C₂₉H₂₇F₃N₆O

Color and Shape: Pale Yellow Solid

Molecular weight: 532.57

Ref: 4Z-P-123001

Ponatinib, Free Base

CAS: 943319-70-8

Ponatinib, Free Base

Formula: C₂₉H₂₇F₃N₆O

Purity: 98%

Color and Shape: Off-white Solid

Molecular weight: 532.55948

Ref: 54-BIM1122

Ponatinib (Standard)

CAS: 943319-70-8

Ponatinib (Standard) is a reference standard for research and analysis in studies involving Ponatinib. Ponatinib (AP24534) is a multi-targeted kinase inhibitor with oral activity that inhibits Abl, PDGFRα, VEGFR2, FGFR1, and Src (IC50=0.37/1.1/1.5/2.2/5.4 nM). Ponatinib has antitumor activity for the treatment of chronic granulocytic leukemia in adults. leukemia.

Formula: C₂₉H₂₇F₃N₆O

Color and Shape: Solid

Molecular weight: 532.56

Ref: TM-TMSM-3391

Ponatinib

CAS: 943319-70-8

Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively

Formula: C₂₉H₂₇F₃N₆O

Purity: 98% - 99.60%

Color and Shape: Solid

Molecular weight: 532.56

Ref: TM-T2372

Ponatinib

CAS: 943319-70-8

Formula: C₂₉H₂₇F₃N₆O

Purity: ≥ 98.0%

Color and Shape: White or off-white powder or crystals

Molecular weight: 532.56

Ref: 7W-GP1345

Ponatinib

CAS: 943319-70-8

BCR-ABL1 tyrosine kinase inhibitor

Formula: C₂₉H₂₇F₃N₆O

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 532.56 g/mol

Ref: 3D-FP27104

Ponatinib Glucuronide

Controlled Product

CAS: 943319-70-8

Formula: C₃₅H₃₅F₃N₆O₇

Color and Shape: Neat

Molecular weight: 709.692

Ref: TR-P688255

Ponatinib

Controlled Product

CAS: 943319-70-8

Applications Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. Potent FAK inhibitor. FGFR/VEGFR/Bcr-Abl inhibitor It is a COVID19-related research product.
References (1) Poch, M. M., et al.: Expert Rev Hematol. 9, 923 (2016) (2) Shamroe, C. L. and Comeau, J. M. Ann Pharmacother. 47, 1540 (2013)(3) Oaxaca, D. M., et al.: Tumour Biol. 37, 12643 (2016)

Formula: C₂₉H₂₇F₃N₆O

Color and Shape: Neat

Molecular weight: 532.56

Ref: TR-P688250

Ponatinib

CAS: 943319-70-8

Formula: C₂₉H₂₇F₃N₆O

Molecular weight: 532.57

Ref: ST-EA-CP-P94000